Whalesbook
📉 The Financial Deep Dive
The Numbers:
Kerala Ayurveda Limited (KAL) disclosed its unaudited financial results for the quarter and nine months ended December 31, 2025, revealing a mixed performance with significant financial challenges.
Standalone Performance:
For the third quarter of FY26 (Q3 FY26), revenue from operations saw a healthy increase of 13.99% YoY to ₹2,206.52 lakhs. However, this top-line growth was overshadowed by a dramatic surge in the loss after tax (PAT), which ballooned to ₹347.32 lakhs from a loss of ₹8.21 lakhs in the prior year's comparable quarter. The nine-month period ending December 31, 2025, mirrored this trend, with revenue growing 14.20% YoY to ₹6,091.96 lakhs, while the PAT loss widened substantially to ₹680.68 lakhs from ₹191.59 lakhs in FY25.
Consolidated Performance:
On a consolidated basis, Q3 FY26 revenue from operations grew 5.88% YoY to ₹3,295.88 lakhs. The consolidated PAT loss for the quarter also widened to ₹459.74 lakhs, compared to a loss of ₹269.59 lakhs in Q3 FY25. However, for the nine months ended December 31, 2025, the consolidated PAT loss showed an improvement, reducing to ₹892.92 lakhs from a larger loss of ₹1,395.90 lakhs in the corresponding period of the previous year. Earnings Per Share (EPS) remained negative across all reported periods.
The Grill:
The company's disclosure did not include any forward-looking guidance from the management regarding future revenue, profitability, or strategic outlook. This absence of commentary leaves investors without clarity on the path to profitability or the company's strategic direction in navigating its financial challenges.
🚩 Risks & Outlook
The company's financial performance raises concerns, with significant deterioration in profitability, particularly on a standalone basis. The planned preferential issue of ₹20.66 crores to convert outstanding unsecured loans from promoter entity Katra Holding Private Limited, and the acquisition of the remaining 26% stake in Ayurvedagram Heritage Wellness Centre for approximately ₹10 crores, funded through equity, point towards potential share dilution for existing investors. While the acquisition aims to make Ayurvedagram a wholly-owned subsidiary, the market will be watching closely how these corporate actions impact the company's financial leverage and shareholder value, especially in light of the persistent losses and negative EPS. The lack of management guidance adds a layer of uncertainty to the near-term outlook, making it crucial for investors to monitor future performance trends and the successful integration of Ayurvedagram.